Propanc Biopharma, Inc.
PPCB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.03 | 0.00 | 0.00 |
| FCF Yield | -9.25% | -0.06% | -0.57% | -3.92% |
| EV / EBITDA | -4.39 | -13.09 | -0.46 | -4.41 |
| Quality | ||||
| ROIC | -32.16% | -23.32% | -274.72% | 7.23% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.40 | 0.01 | 0.00 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 310,291.46% | 310,291.46% | -100.00% | -100.00% |
| Free Cash Flow Growth | -7,032.59% | 80.04% | -2,071.84% | 97.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | -0.45 | -0.02 | -3.89 |
| Interest Coverage | 15.29 | -14.32 | -510.65 | -1.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 15.96 | -19,851.57 | -25,413.86 |